News Articles for Paul Watt

Avicena awarded $3m grant for consortium

Bookmark

Save articles for future reference.

Subscribe to BN Log In

Share to

• Facebook
• X
• LinkedIn

Perth-based medical technology company Avicena Systems has won a $3 million grant from the federal Department of Industry, Science and Resources for a collaborative research partnership with the University of New South Wales.

Tech startup improves with age

Bookmark

Save articles for future reference.

Subscribe to BN Log In

Share to

• Facebook
• X
• LinkedIn

Perth company Avicena Systems aims to confirm research finding that tech startups established by older founders have a higher chance of success.

Avicena gains TGA authorisation

Bookmark

Save articles for future reference.

Subscribe to BN Log In

Share to

• Facebook
• X
• LinkedIn

West Perth company Avicena Systems has ticked off another big achievement, with the Therapeutic Goods Administration authorising its locally developed diagnostic technology.

WA start-up in FIFO trial

Bookmark

Save articles for future reference.

Subscribe to BN Log In

Share to

• Facebook
• X
• LinkedIn

A COVID-19 screening system designed by West Perth start-up Avicena Systems has been cleared for use in a large-scale trial in the state's fly-in, fly-out workforce.

Incite celebrates WA’s tech success

Bookmark

Save articles for future reference.

Subscribe to BN Log In

Share to

• Facebook
• X
• LinkedIn

From Pilbara driverless trains to rapid virus testing, WA minds have created innovative technology.

Avicena wins three Incite awards

Bookmark

Save articles for future reference.

Subscribe to BN Log In

Share to

• Facebook
• X
• LinkedIn

Avicena Systems, Vix Technology and East Metropolitan Health Service were among the winners at the annual Incite Awards for WA tech.

Big data benefits kids

Bookmark

Save articles for future reference.

Subscribe to BN Log In

Share to

• Facebook
• X
• LinkedIn

AI can find answers to childhood disease, with the right data and researchers.

WA company develops new virus tester

Bookmark

Save articles for future reference.

Subscribe to BN Log In

Share to

• Facebook
• X
• LinkedIn

A Perth startup led by three tech veterans is planning to manufacture and export a new high-speed COVID testing machine after getting backing from the state government.

Heathcare projects receive $1.2 million boost

Bookmark

Save articles for future reference.

Subscribe to BN Log In

Share to

• Facebook
• X
• LinkedIn

Federally-funded MTPConnect has announced a $1.2 million commitment to two healthcare projects, both of which involve Telethon Kids Institute as a collaborator.

Bringing business on board

Bookmark

Save articles for future reference.

Subscribe to BN Log In

Share to

• Facebook
• X
• LinkedIn

A leading medical researcher at the Telethon Kids Institute believes effective communication is key if the business community is to become more engaged in research into autism.

Biotechs bleed cash in search for profit

Bookmark

Save articles for future reference.

Subscribe to BN Log In

Share to

• Facebook
• X
• LinkedIn

WA biotechs are drowning in a sea of red as yet more negative results are reported.

Hopkins chief at Phylogica

Bookmark

Save articles for future reference.

Subscribe to BN Log In

Share to

• Facebook
• X
• LinkedIn

Phylogica chief scientist Richard Hopkins has been appointed as chief executive officer and a board member, switching roles with Paul Watt.

Phylogica appoints chief scientist as new CEO

Bookmark

Save articles for future reference.

Subscribe to BN Log In

Share to

• Facebook
• X
• LinkedIn

Perth-based biotechnology company Phylogica has appointed Richard Hopkins chief executive officer as part of wider management changes aimed at pursuing work opportunities with other research c

Phylogica wins $1.5m deal

Bookmark

Save articles for future reference.

Subscribe to BN Log In

Share to

• Facebook
• X
• LinkedIn

Perth-based drug discovery and biotechnology company Phylogica has signed a deal with major pharmaceutical operator AstraZeneca and its biologics unit MedImmune this week, a positive step for an industry that has had underwhelming investment and returns i